Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Arch Pediatr ; 27(7): 372-379, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32919843

ABSTRACT

BACKGROUND: Children younger than 36 months with fever without a source (FWS) are at risk of serious bacterial infections (SBI). The risk of occult bacteremia (OB) has been greatly reduced in vaccinated children. The aim of this study is to describe the epidemiology of SBI in children with FWS in our setting and to evaluate the performance of our management algorithm. METHODS: We designed a prospective cohort study. We included children aged 0-36 months presenting with FWS in our emergency unit. Demographic and clinical characteristics, investigations, and management procedures were recorded at the time of inclusion. Information on clinical evolution, final diagnosis, and immunization history were obtained after 10 days. Potential predictors of SBI were compared between patients with and without SBI. RESULTS: Between October 2015 and September 2017, 173 children were recruited, with a median age of 4.4 months (2.1-1). Of these children, 166 (96%) were up to date with their vaccinations. A total of 47 children (27%) had a final diagnosis of SBI, which were all urinary tract infections (UTI). Presence of chills (odds ratio [OR] 5.6, 95% confidence interval [CI] 1.3-24.3), fever for>2 days (OR 29.1, 95% CI 3.5-243.5), and age<9 months (OR: 45.3, 95% CI: 4.9-415.7) were statistically significant predictors of UTI in a multivariate logistic regression. The sensitivity and specificity of our management algorithm were 100% (95% CI: 92.4-100%) and 21.4% (14.6-29.6%), respectively. CONCLUSIONS: In the setting of high vaccination coverage, we only identified SBI related to UTIs. We could not identify any OB. Our management algorithm was able to identify all SBI, but specificity was low. Refined criteria for screening of UTI could slightly increase this.


Subject(s)
Bacterial Infections/complications , Bacterial Infections/diagnosis , Clinical Decision Rules , Fever of Unknown Origin/etiology , Urinary Tract Infections/complications , Urinary Tract Infections/diagnosis , Algorithms , Bacterial Infections/epidemiology , Bacterial Infections/therapy , Case-Control Studies , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Logistic Models , Male , Prevalence , Prospective Studies , Risk Assessment , Risk Factors , Sensitivity and Specificity , Severity of Illness Index , Switzerland/epidemiology , Treatment Outcome , Urinary Tract Infections/epidemiology , Urinary Tract Infections/therapy
2.
Rev Med Suisse ; 11(470): 872-6, 2015 Apr 15.
Article in French | MEDLINE | ID: mdl-26050305

ABSTRACT

Leptospirosis is a zoonosis found worldwide, with an incidence that is approximately 10 times higher in the tropics than in temperate regions. The main reservoir of leptospirosis is the rat and human infection usually results from exposure to infected animal urine or tissues. Only 10% of cases are symptomatic. We present here two confirmed and two probable cases of leptospirosis in a family returning from whitewater rafting in Thailand, illustrating the wide variety of the clinical manifestations of this infection. Two of the patients were hospitalized and presented a probable Jarisch-Herxheimer reaction after initiation of beta-lactam therapy. The two others patients were treated empirically with doxycycline. We discuss here some relevant aspects of the epidemiology, clinical manifestations, therapy and the challenge of an early diagnosis of leptospirosis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Leptospirosis/epidemiology , Zoonoses/epidemiology , Adolescent , Adult , Animals , Anti-Bacterial Agents/adverse effects , Female , Humans , Leptospirosis/diagnosis , Leptospirosis/drug therapy , Male , Recreation , Rivers , Thailand/epidemiology , Travel , Zoonoses/diagnosis , Zoonoses/drug therapy , beta-Lactams/adverse effects , beta-Lactams/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...